Pediatrix Medical Group, Inc. quarterly report, Q1 FY2020

Business context and reporting period

This is MEDNAX, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2020. The filing describes a physician-services business, including neonatal, radiology, maternal-fetal, pediatric and anesthesia services. The supplied company metadata says Pediatrix Medical Group, but the filing itself identifies the registrant as MEDNAX, Inc.

MEDNAX had sold its MedData management-services business in October 2019, which is reported as discontinued operations in the comparison. After quarter-end, on May 6, 2020, the company completed the sale of its anesthesiology medical group.

Financial performance and liquidity

Revenue declined 0.6% year over year; same-unit revenue fell 1.0%, including a 2.0% volume decline partly offset by a 1.0% increase from reimbursement-related factors. Operating margin contracted to 1.6% from 9.2%; excluding $30.9 million of transformation and restructuring expenses, management reported operating income of $44.0 million and a 5.2% margin. Practice salaries and benefits rose 5.0% to $652.7 million, while general and administrative expense increased to $105.2 million, or 12.4% of revenue.

At March 31, cash and cash equivalents were $312.2 million and short-term investments were $85.0 million, versus cash of $112.8 million at year-end 2019. Working capital was $594.5 million. Cash from operations was negative, with management citing lower earnings and payments of annual performance-based compensation as key factors. Capital expenditures were $13.7 million.

Debt principal included $368.5 million outstanding on the revolving credit facility, $750 million of 5.25% notes due 2023 and $1.0 billion of 6.25% notes due 2027. Revolver availability was $531.3 million after the facility’s temporary capacity reduction. The company reported compliance with applicable covenants and said it expected to remain compliant; its amended facility requires minimum availability of $300 million and weekly repayments from unrestricted cash above $300 million, subject to a reserve and other terms.

Material changes, outlook and risks

• COVID-19: From mid-March, elective anesthesia procedures, non-urgent radiology studies and appointments at office-based practices declined. The company reported no significant NICU volume impact to date. Management expected COVID-19 to materially affect results but said the ultimate effect could not be predicted.
• Mitigation and aid: The company reduced executive and other employee compensation, furloughed some non-clinical staff, cut operating costs and suspended most transformation initiatives. Affiliated practices received $12.2 million of initial CARES Act provider aid in early April; eligibility for further aid was uncertain. The company intended to defer employer Social Security taxes during 2020.
• Anesthesia divestiture: The May 6 sale generated $50 million cash, subject to customary adjustments, plus a contingent economic interest valued from $0 to $250 million. MEDNAX retained anesthesia receivables; net of certain working-capital items, these were approximately $110 million at March 31. The company anticipated a disposal loss of approximately $500–$600 million, subject to final valuation.
• Other financial pressures: Management anticipated continued above-historical growth in clinician compensation and malpractice expense. Professional-liability obligations totaled $286.5 million, partly self-insured; insurance recoveries and coverage limitations affect ultimate exposure.
• Contingencies and regulation: The filing discusses ordinary-course government audits and medical-malpractice claims, whose outcomes are uncertain. It also identifies potential effects from healthcare reimbursement and policy changes, including surprise-billing legislation, Medicaid changes and ACA-related litigation.
• Formal guidance: The filing provides no specific full-year revenue or earnings guidance. Management said it expected sufficient liquidity to meet obligations for at least the next 12 months, while emphasizing uncertainty around the pandemic’s effects.

Important facts for investors to verify

1. Confirm the entity and reporting scope: the supplied metadata names Pediatrix Medical Group, while this filing is issued under MEDNAX, Inc.
2. Track COVID-19 volume and collection trends by service line, including whether deferred care returns and whether receivable days (51.3 at quarter-end) worsen.
3. Review the final accounting for the anesthesia divestiture, including the estimated $500–$600 million disposal loss, retained receivables and contingent consideration.
4. Monitor revolver availability, the $300 million minimum-availability requirement, leverage covenants and cash repayment provisions.
5. Separate continuing-operations performance from discontinued-operation losses and assess adjusted metrics alongside GAAP results.